Back

Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in obese patients with valvular heart disease: a target-trial emulation

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Epidemiology, prognosis, and outcome in valvular heart disease: right ventricular and heart failure Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Hatim Kerniss

University Heart Centre Frankfurt, University Hospital Frankfurt, Frankfurt am Main (Germany)

5 More presentations in this session

Presentation thumbnail
Prognosis of combined moderate aortic stenosis and moderate mitral regurgitation
Doctor E. Prinz (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
ASNet: mortality and valve replacement prediction in patients with aortic stenosis using explainable artificial intelligence in a multi-ethnic asian cohort
Doctor E. Lim (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Enrichment and spatial convergence of transthyretin, OxPL, plasminogen and Lp(a) in calcific aortic valve stenosis
Professor M. Torzewski (Stuttgart, DE)
Abstract Slides Video
Presentation thumbnail
Transforming valvular heart disease detection and management: insights from a mobile screening program using handheld ultrasound
Doctor M. Dupuy (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Nationwide practise patterns and regional differences in antibiotic treatment of streptococcal infective endocarditis in Denmark
Miss I. Knudsen (DK)
Abstract Slides Video

Access the full session

Session thumbnail
Epidemiology, prognosis, and outcome in valvular heart disease: right ventricular and heart failure

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Association of SGLT2-inhibitor and GLP1-receptor agonist use with clinical outcomes in aortic stenosis: a large-scale propensity-matched study
28 August 2026
thumbnail
Congress Presentation
The efficacy and safety of GLP-1 agonists to modify cardiovascular morbidity in patients with obesity without diabetes mellitus: a meta-analysis involving 32,884 patients
1 September 2024
thumbnail
Congress Presentation
Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure
31 August 2025
thumbnail
Congress Presentation
Comparative effectiveness of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis with intervention ranking
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources